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Background: Loss of function COQ2 mutations results in primary CoQ10 deficiency. Recently, recessive mutations
of the COQ2 gene have been identified in two unrelated Japanese families with multiple system atrophy (MSA). It
has also been proposed that specific heterozygous variants in the COQ2 gene may confer susceptibility to sporadic
MSA. To assess the frequency of COQ2 variants in patients with MSA, we sequenced the entire coding region and
investigated all exonic copy number variants of the COQ2 gene in 97 pathologically-confirmed and 58 clinically-
diagnosed MSA patients from the United States.
Results: We did not find any homozygous or compound heterozygous pathogenic COQ2 mutations including
deletion or multiplication within our series of MSA patients. In two patients, we identified two heterozygous COQ2
variants (p.S54W and c.403 + 10G > T) of unknown significance, which were not observed in 360 control subjects.
We also identified one heterozygous carrier of a known loss of function p.S146N substitution in a severe MSA-C
pathologically-confirmed patient.
Conclusions: The COQ2 p.S146N substitution has been previously reported as a pathogenic mutation in primary
CoQ10 deficiency (including infantile multisystem disorder) in a recessive manner. This variant is the third primary
CoQ10 deficiency mutation observed in an MSA case (p.R387X and p.R197H). Therefore it is possible that in the
heterozygous state it may increase susceptibility to MSA. Further studies, including reassessing family history in
patients of primary CoQ10 deficiency for the possible occurrence of MSA, are now warranted to resolve the role of
COQ2 variation in MSA.
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Multiple system atrophy (MSA) is a rare sporadic neuro-
degenerative disorder, with an estimated prevalence ran-
ging from approximately 2–5 cases per 100,000 people
[1]. This devastating and rapidly progressive disease is
characterized clinically by combinations of poor levo-
dopa responsive parkinsonism, autonomic failure, cere-
bellar ataxia, and pyramidal symptoms [1,2]. Widespread
presence of glial cytoplasmic inclusions is the neuro-
pathologic hallmark of MSA [3]. To date, there are no* Correspondence: ross.owen@mayo.edu
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unless otherwise stated.effective therapies for MSA and our understanding of
the disease etiology remains limited.
Recently, a homozygous mutation p.M128V-V393A/
p.M128V-V393A (referred to by Tsuji and colleagues as
p.M78V-V343A/p.M78V-V343A) and compound heterozy-
gous mutations p.R387X/p.V393A (referred to by Tsuji and
colleagues p.R337X/p.V343A) in the coenzyme Q2 4-
hydroxybenzoate polyprenyltransferase gene (COQ2; OMIM
609825) were identified in affected members of two unre-
lated Japanese families with MSA [4]. This is the first report
of recessive COQ2 pathogenic mutations in adults, however
recessive COQ2 mutations are known to cause primary co-
enzyme Q10 (CoQ10) deficiency-1 (COQ10D1; OMIM
607426) which includes phenotype of infantile multisystem
disorder or nephrotic syndrome [5-12]; COQ2 is involvedtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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ported that specific heterozygous variation (p.V393A) in
the COQ2 gene may affect susceptibility to MSA [4].
Given these findings, we screened the Mayo Clinic Florida
series of 155 MSA patients to assess the frequency of
COQ2 variants in disease. Given the proposed loss-of-
function mechanism we also investigated exon dosage as a
possible disease-related phenomenon.
Results
Result of sanger sequencing and copy number assay
In this study, our sequence analysis of COQ2 in 155 MSA
patients identified eleven variants including one intronic,
six synonymous, three non-synonymous and one nonsense
variants (Table 1), however exon dosage assays did not de-
tect any deletion/multiplication. Four variants are com-
mon, p.R22X, p.L66V, p.D298D and p.S330S, and present
in the Exome Variant Server (EVS) and 1000 Genomes;
there was no significant minor allele frequency (MAF) dif-
ference with our patients, EVS data, or 1000 Genomes
data (Table 1; Additional file 1). We found one homozy-
gous and five heterozygous carriers of p.R22X in 155 MSA
patients, but there was no significant difference between
patients and control subjects or patients and EVS data
or 1000 Genomes data (Table 1; Additional file 1). This
variant is incorporated into one of the longer COQ2 tran-
scripts (Figure 1); given the frequency of this variant and
the presence of homozygotes both in our study and the
EVS, it is unlikely this variant is of clinical relevance in
primary CoQ10 deficiency or MSA. Indeed, Schottlaender
and Houlden recently reported that p.R22X was more
common in controls than cases [13].
Rare heterozygous variants: p.R10R, p.S54W, c.403 +
10G >T (Exon1 + 10), p.P142P, p.S146N, p.A267A and p.
Y369Y were observed in one patient each but p.S54W,
c.403 + 10G >T (Exon1 + 10) and p.S146N were not found
in 360 control subjects. Sequencing for p.R10R, p.P142P,
p.A267A, p.D298D, p.S330S and p.Y369Y was not assessed
in controls because they are synonymous variants. In total,
we identified three COQ2 variants with unknown signifi-
cance; p.S54W, c.403 + 10G >T (Exon1 + 10) and p.S146N.
The COQ2 p.S146N [6-8] has been shown to affect COQ2
function [7] and was not identified in 500 control chromo-
somes in a previous report [6].
Statistical analysis for nine COQ2 mutations found in
CoQ10 deficiency-1
Primary CoQ10 deficiency-1 is extremely rare; only 11 pa-
tients and nine COQ2 mutations have been identified so far
(Table 2) [5-12]. We investigated the publicly available data
(EVS) and these nine variants (p.S109N, p.S146N, p.R197H,
p.N228S, p.L234fsX247, p.T297C, p.A302V, p.R387X and
p.N401fsX15) were not found in more than 4000 European
American subjects. If we perform a meta-analysis of theresults from our study, the other case–control studies
[4,13,17,18] and EVS data, pathologically-confirmed
MSA is associated with COQ2 mutations previously
found in primary CoQ10 deficiency-1 (2/361 vs 0/6356,
p value =0.0029, Table 3); clinical MSA did not associate
with those nine mutations. (1/1907 vs 0/6356, p value =0.23,
Table 3).
In silico analysis
For the c.403 + 10G > T (Exon1 + 10) variant, in silico ana-
lysis, Human Splicing Finder predicted this variant to
change exon 1 splicing site including 8 intronic nucleo-
tides between exon 1 and 2. We performed RNA/cDNA
study to validate whether the heterozygous c.403 + 10G >
T (Exon1 + 10) caused a splicing effect in the border be-
tween exon 1 and 2.
For the COQ2 protein domain, TIGRFAMS domain
showed 4-hydroxybenzoate polyprenyl transferase (Acces-
sion: TIGR01474) and Pfam database showed UbiA pre-
nyltransferase family (Accession: PF01040) respectively
(Figure 1). Main roles of those domains are biosynthesis of
cofactors, prosthetic groups, and carriers. We did not find
any specific relationship between COQ2 variants and pro-
tein domains (Figure 1), although there is a tendency that
the most of variants found in CoQ10 deficiency-1 exist in
those of domains found in TIGRFAM and Pfam.
RNA/cDNA sequencing
RNA/cDNA sequencing showed normal sequence be-
tween exon 1 and 2 (after p.R22X) from the cerebellum
tissue with homozygous or heterozygous p.R22X (data
not shown), suggesting the isoform including first ATG
(ENST00000311469) does not play major role in MSA
patients (Figure 1). Mitsui and Tsuji reported that the
majority of the transcripts in human tissues start near
the third or fourth ATG codon [19] and p.R22X lies up-
stream of the third ATG codon (Figure 1). Analysis of
the transcript generation for the carrier of the c.403 +
10G > T (Exon1 + 10) variants did not show any alter-
nate band length and sequencing of the amplified cDNA
product did not show any alternate nucleotide inclusion.
Clinical and pathological presentation of a patient with
heterozygous COQ2 p.S146N variant
This patient was a Caucasian male who had been clinically
diagnosed with MSA-C (cerebellar variant of MSA) during
his life. There is no family history of any similar disorder
or other neurological disorders. His initial symptoms were
staggering gait and frequent falls at the age of 54 years. A
brain MRI showed marked atrophy of the pontine and
cerebellar vermis at the age of 55 years. He had deteri-
oration of his coordination, with not only worsening of
his gait but also of his limbs and speech difficulties.
Autonomic dysfunction included difficulty emptying the
Table 1 Variants of COQ2 observed in this study
Exon Exon 1 Exon 1 Exon 1 Exon 1 Intron 2 Exon 2 Exon 2 Exon 5 Exon 5 Exon 6 Exon 7
rs number rs183012002 rs112033303 rs376396608 rs6818847 rs121918233 rs199581249 rs6535454 rs1129617 rs141431344
Genotypea c.30G > A c.64A > T c.161C > G c.196G > T c.403 + 10G > T c.426A > G c.437G > A c.801G > A c.894 T > C c.990C > T c.1107C > T
Amino acid changeb p.R10R p.R22X p.S54W p.L66V Exon1 + 10 p.P142P p.S146N p.A267A p.D298D p.S330S p.Y369Y
Cases Cases Cont. Cases Cont. Cases Cont. Cases Cont. Cases Cases Cont. Cases Cases Cases Cases
Major allele 154 149 339 154 360 87 175 154 360 154 154 360 154 85 89 154
Heterozygous allele 1 5 20 1 0 54 146 1 0 1 1 0 1 64 59 1
Minor allele 0 1 1 0 0 14 39 0 0 0 0 0 0 6 7 0
Total 155 155 360 155 360 155 360 155 360 155 155 360 155 155 155 155
MAF (%) 0.3 2.3 3.1 0.3 0 26.5 31.1 0.3 0 0.3 0.3 0 0.3 24.5 23.5 0.3
OR (95% CI) NA 0.65 (0.0.21, 1.71) NA 0.74 (0.50, 1.10) NA NA NA NA NA NA NA
P-value NA 0.51 0.30 0.12 0.30 NA 0.30 NA NA NA NA
PolyPhen-2 NA NA Benign Benign NA NA Probably damaging NA NA NA NA
SIFT Tolerated NA Tolerated Tolerated NA Tolerated Damaging Tolerated Tolerated Tolerated Tolerated
acDNA reference (NM_015697.7) from NCBI gene was used to annotate the position of genomic DNA. bAccession number NP_056512.5 from NCBI protein were used to annotate the position of amino acid. P-values result from
Fisher’s exact test comparing the frequency of carriers of the minor allele between MSA patients and controls. Estimation of an odds ratio (and 95% confidence interval) is not possible when the rare allele is not observed in
one of the comparison groups, and therefore NA is given for these quantities for three of the variants for which the rare allele was observed in MSA patients but not in controls. After applying a Bonferroni adjustment for


















Figure 1 COQ2 variants and transcripts. The upper three panels in blue represents the protein coding transcripts of the COQ2 gene and the exons
are numbered (transcripts which cause nonsense mediated decay or transcripts which produce no protein are not shown). Transcripts and protein
domains are referred to Ensemble (http://useast.ensembl.org/index.html) and 1000 Genomes (http://www.1000genomes.org/home). The lower three
panels represent the protein domains and motifs by Forsgren and colleagues [14], TIGRFAMs database (www.tigr.org/TIGRFAMs) [15] and Pfam
database (http://pfam.xfam.org/) [16]. There were no transcripts which start from second ATG. Red box indicates the allylic polyprenyl diphosphate
substrate-binding site. Purple Boxes indicate the six transmembrane domains (TMD) predicted. The orange box and green box show the areas of
4-hydroxybenzoate polyprenyl transferase (Accession: TIGR01474) and UbiA prenyltransferase family (Accession: PF01040) respectively. Potential risk
variants and p.R22X shown in black were identified in multiple system atrophy (MSA) [4,13,17]. p.R22X only exists on the longest isoform, COQ2-001,
and does not associated with MSA. †ENST00000439031 was missing in the latest Ensembl release 77 - October 2014. *Asterisks indicate variants found
in our MSA series. Arrow shows an intronic variant, c403 + 10G > T (Exon1 + 10). Mutations in blue were identified in primary coenzyme Q10 (CoQ10)
deficiency [5-12]. Mutations in red (p.S146N, p.R197H and p.R387X) were identified both in MSA and primary CoQ10 deficiency [4,6,8,13].
Table 2 COQ2 mutations previously found in primary CoQ10 deficiency-1
# Amino acid change Age at
onset
Age at death Clinical phenotype Reference
1 p.S109N/p.S109N 3 week 5 month Seizures, hypertrophic cardiomegaly, nephrotic syndrome [5]
2 p.S146N/p.S146N 5 day 6 month Nephrotic syndrome, seizures, encephalopathy, hypotonia,
respiratory failure
[6]
3 p.S146N/p.S146N Not-available Not-available Not available [7]
4 p.S146N/p.R387X birth 2 month Respiratory failure, lactic acidosis, hypertrophic cardiomyopathy,
necrotizing enterocolitis, encepharopathy
[8]
5 p.R197H/p.N228S 18 month alive at
29 month
Nephrotic syndrome, generalized edema [6]
6 p.N228S/p.L234fsX247 24 month Not-available Nephrotic syndrome, acute renal failure [9]
7 p.T297C/p.T297C (proband) 12 month alive at
33 month




8 p.T297C/p.T297C (sister) 9 month Not-available Nephrotic syndrome [10]
9 p.A302V/p.A302V (twin,
male)
birth 6 month Respiratory failure, generalized edema, seizures, hypotonia,




birth 5 month Respiratory failure, generalized edema, seizures, hypotonia,
dystonic-hyper kinetic movement, lactic acidosis, intracranial hemorrhage
[11]
11 p.N401fsX15/p.N401fsX15 birth 12 day Neurologic distress, liver failure, nephrotic syndrome, pancytopenia,
diabetes, cytolysis, seizures, lactic acidosis
[12]
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Table 3 Frequency of nine COQ2 mutations found in CoQ10 deficiency-1
















This study USA p.S146N 0/58 (0) 1/97 (1.0) 1/155 (0.6) NA NA NA NA
Tsuji et al. [4] 2mixed p.R387X 1/762 (0.1) 0/2 (0.0) 1/764 (0.1) 0/1129 (0) 0.40 NA 0.40
Jeon et al. [17] Korea None 0/299 (0) NA 0/299 (0) 0/365 (0) 1.00 NA 1.00
Sharma et al. [18] Europe None 0/788 (0) NA 0/788 (0) 0/600 (0) 1.00 NA 1.00
Schottlaender
et al. [13]
Europe p.R197H NA 1/300 (0.3) 1/300 (0) 0/262 (0) NA 1.00 1.00
1EVS USA None NA NA NA 0/4000 (0) NA NA NA
Combined Combined p.S146N, p.R197H
or p.R387X
1/1907 (0.05) 2/361* (0.5) 3/2268 (0.1) 0/6356 (0) 0.23 0.0029 0.019
Total nine COQ2 mutations previously found in primary CoQ10 deficiency-1, p.S109N, p.S146N, p.R197H, p.N228S, p.L234fsX247, p.T297C, p.A302V, p.R387X and p.
N401fsX15, were not found in more than 4000 subjects of EVS. 1Data of European American population from Exome Variant Server. 2Mixed indicates Japan, Europe and
North America. Abbreviation: EVS, Exome Variant Server, MSA, multiple system atrophy, NA, not available. *Thirty eight out of 97 our patients were included in the study
of Schottlaender et al. P-values result from Fisher’s exact test. Because only two pathologically-confirmed MSA patients were included in the study by Tsuji et al., we did
not make a comparison of pathologically confirmed MSA patients vs. controls for that study.
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dysfunction was otherwise suggested by several syncopal
episodes. He was wheelchair bound at the age of 60 years.
Muscle strength was normal. Deep tendon reflex were ab-
normally brisk at all sites and bilateral Babinski sign was
positive. Severe ataxia was seen on finger to nose to finger
test and heel-knee-shin testing. His treatment was limited
to speech and physical therapy. He died of septicemia at
the age of 68 years.
He had an autopsy examination (Figure 2). The fixed tis-
sue of the case weighted 680 grams and the calculated
brain weight was 1360 grams. The infratentorial tissues
were remarkable for severe atrophy of the pontine base
and the inferior olive (Figure 2A). Horizontal sections of
the midbrain, pons and medullar were remarkable for ex-
tremely marked atrophy. The substantia nigra had loss of
pigmentation. The cerebrum peduncle was severely atro-
phic (Figure 2B, arrowheads). Microscopic analysis showed
the neocortex was unremarkable in most areas. The pon-
tine base and the inferior olive had severe neuronal loss
and gliosis. In addition there were GCIs (Figure 2F & G).
The cerebellum had severe diffuse loss of Purkinje cells
with many axonal torpedoes. The internal granular cell
layer had diffuse depopulation. The deep cerebellar white
matter was markedly attenuated and gliotic with GCIs
(Figure 2H). The pathological findings were of MSA (stria-
tonigral and olivopontocerebellar degeneration), though
the degree of the α-synuclein pathology was more severe
than for typical MSA cases.
Discussion
Our study examined the relevance of COQ2 variation (and
subsequent CoQ10 deficiency) in susceptibility to MSA.
The absence of pathogenic recessive COQ2 mutations or
copy number variants within our series of clinical andpathologically-confirmed MSA patients means further
screening of case–control series and functional studies are
likely required to confirm the role of this candidate gene
in MSA. We identified two heterozygous COQ2 variant,
p.S54W and c.403 + 10G > T, of unknown significance, al-
though cDNA study for c.403 + 10G > T did not show any
alternate splicing. Recently, three independent case–con-
trol studies also reported an absence of recessive COQ2
mutations in MSA supporting the rarity of this as a po-
tential cause of disease [13,17,18]. In addition, Jeon and
colleagues noted the Asian-specific genetic risk factor p.
V393A was observed at the same frequency in cases and
controls (~2.6%). These reports question the role of
COQ2 variants in risk of MSA but do not rule out the po-
tential for rare variants in disease.
Interestingly, we found one heterozygous COQ2 p.
S146N variant. Clinical and pathological presentation of
our Caucasian patient harboring the heterozygous p.S146N
variant was MSA-C with severe pathological changes. This
mutation has been previously reported as a pathogenic
homozygous mutation in infantile multisystem disorder
(a major phenotype of primary CoQ10 deficiency-1) [6,7]
or as part of a compound heterozygous state [8] (Table 2).
The pathogenicity of this mutation is supported by the
high conservation at this amino acid position, by the pre-
diction as probably damaging by PolyPhen-2 and SIFT, and
by the finding of abnormal mitochondria proliferation and
low CoQ10 levels in the skeletal muscle of carriers [6].
The study of Bujan and colleagues demonstrated that
a patient carrying the homozygous p.S146N mutation
showed significant CoQ10 deficiency in fibroblasts and
presented deficient CoQ10 biosynthesis [7]. Collectively,
these reports suggest that the p.S146N substitution func-
tionally impairs CoQ10 activity and therefore it is pos-
sible that in the heterozygous state p.S146N might
Figure 2 Macroscopic features and α-synuclein pathology of a patient with heterozygous COQ2 p.S146N variant (A-H). The infratentorial
tissues were remarkable for severe atrophy of the pontine base and the inferior olive (A). The trigeminal nerve was unusually prominent due to
the extreme pontine atrophy (arrows). Horizontal sections of the midbrain were remarkable for extremely marked atrophy (B). The substantia
nigra had loss of pigmentation. The cerebrum peduncle was severely atrophic (B, arrowheads). Immunohistochemical staining for α-synuclein
(LB509, mouse monoclonal; 1:100) in the globuls pallidus (C), putamen (D), substantia nigra (E), pontine nucleus (F), inferior olive (G) and the
cerebellar white matter (H) (magnification × 400).
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gous p.S146N was clinically diagnosed as MSA-C. Fitting
with this, it was reported that patients with COQ2 mu-
tations have increased frequency of MSA-C compared to
MSA-P (the parkinsonian variant of MSA) and the cerebel-
lum is more vulnerable to compromised COQ2 function
than other regions of the central nervous system [4]. A pre-
vious study has also revealed that the cerebellum in both
rats and humans contains the lowest concentration of
CoQ10 in the brain [20]. Recessive COQ2 mutations are
known to cause primary CoQ10 deficiency-1, includinginfantile multisystem disorder, it remains unresolved why
the same gene would cause MSA in an adult [5-12]. One
possible explanation would be that the decrease in COQ2
activity associated with the recessive mutations in patients
with MSA is milder than that observed in patients with pri-
mary CoQ10 deficiency-1 [4].
This report is the third time a mutation known to cause
primary CoQ10 deficiency-1 has been observed in an
MSA case. Recently Tsuji and colleagues found R387X (re-
ferred to R337X by Tsuji et al.) in one of the original mul-
tiple families (Family 12) and Schottlaender and Houlden
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p.R197H carrier in 300 pathologically-confirmed MSA [13].
COQ2 mutations found in CoQ10 deficiency-1 were associ-
ated with MSA (3/2268 vs 0/6356, p value =0.019, Table 3),
especially pathologically-diagnosed MSA (p value =0.0029).
Although primary CoQ10 deficiency-1 due to COQ2 mu-
tations is rare, it may be worth reassessing family history
in these patients for the possible increased occurrence of
MSA.
Previously, several genetic risk factors for MSA have been
reported. For instance, a common variant in the α-synuclein
gene (SNCA rs11931074) was associated with MSA in an
initial study (Odds ratio [OR] = 6.2, 95% confidence interval
[CI]: 3.4 – 11.2, p value under recessive model =5.5 × 10−12)
[21] and this result was subsequently replicated in an inde-
pendent set of pathologically-confirmed MSA cases (OR:
4.7, 95% CI: 1.0 – 21.7, p value =0.06) [22]. Another
common variant, the microtubule-associated protein tau
(MAPT) H1 haplotype (rs1052553) has also been asso-
ciated with risk of MSA (OR: 1.9, 95% CI: 1.1 – 3.2,
p =0.016) [23]. On the other hand, rare variants (MAF <
1%) have not been reported to be associated with MSA,
probably due to the low disease frequency of MSA. Copy
number loss of “src homology 2 domain containing-
transforming protein 2 gene” was reported as a risk of
MSA [24] but a replication study from another institute
failed to show the association [25]. Further studies of rare
variants and copy number variation are warranted to elu-
cidate further genetic risks for MSA.
Conclusions
MSA due to recessive COQ2 mutations (including exon
dosage) was not observed in our study. We did detect
the presence of a single heterozygous pathogenic COQ2
variant, which causes infantile multisystem disorder (pri-
mary CoQ10 deficiency-1) in a homozygous condition.
Given the lack of therapeutic options in MSA, more
work is warranted to resolve the role, if any, of COQ2
variants in disease. Primary CoQ10 deficiencies, with
early treatment, respond well to CoQ10 supplementation
[26]. Whether this is a viable option for treatment or
prevention of MSA, or within in a small subset of indi-
viduals carrying COQ2 mutations, remains to be deter-
mined. Further studies on the etiology of MSA will lead
to more rational and improved drug discovery.
Methods
Subjects
A total of 97 pathologically-confirmed MSA patients, 58
clinically-diagnosed MSA patients, and 360 control sub-
jects from the United States were included in this study
(Table 4). Thirty eight pathologically-confirmed MSA
cases were included in a previous study as part of the
MSA brain collaboration study [13]. The diagnosis ofMSA was made using current consensus criteria [2]. In
MSA patients, mean age was 61.6 ± 9.1 years, and 93 pa-
tients (60%) were male. Mean age at evaluation in con-
trols was 70.0 ± 13.4 years, and 142 control subjects
(39.4%) were male. All control individuals were free of
personal or familial history suggestive of parkinsonism,
cerebellar ataxia or autonomic failure. All individuals
were unrelated within and between sample groups. The
Mayo Clinic Institutional Review Board approved the
study, and all living subjects provided informed consent.
Informed consent for pathologically-confirmed cases
was obtained from the next-of-kin.
Genetic analysis
For direct sequence analysis, each exon was amplified by
polymerase chain reaction (PCR) using published primers
for COQ2 [4]. DNA was extracted from frozen brain or
whole blood samples using standard protocols. Electrophe-
rograms were analyzed with SeqScape v2.5 using 3730
DNA Analyzer (ABI, Applied Biosystems, Foster City, CA,
USA). Specific genetic variants observed (p.R22X, p.S54W,
p.L66V, Exon1 + 10 and p.S146N) on exon 1 and 2 were
screened through a series of US Caucasian healthy control
subjects (n = 360) but synonymous (silent) variants were
not screened. Of note, COQ2 gene has multiple start co-
dons and a number of alternative isoforms are expressed.
Herein, we have used the consensus RefSeq accession
NM_015697.7 to number all variants within the COQ2
gene and protein; however this does not necessarily indi-
cate this long isoform is the one related to the MSA or pri-
mary CoQ10 deficiency phenotype.
Exonic deletion or multiplication of COQ2 gene was
assessed in all patients with MSA. To determine exon dos-
age genomic copy number probes were used for each indi-
vidual exon (n = 7; Applied Biosystems) and details are
available on request. TaqMan Copy Number Reference
Assay RNase P (human) was used as an endogenous con-
trol (ABI). Quantitative PCR was carried out using Taq-
Man expression chemistry protocol as previously described
[27]. All assays were performed in triplicate on the ABI
7900HT Fast Real-Time PCR System and analyzed with
ABI SDS 2.2.2 Software (ABI).
RNA/cDNA sequencing
RNA was extracted from brain tissue (cerebellum) using
standard protocol with TRIzol reagent (Life Technologies,
Foster City, CA, USA). For carriers of specific variation,
p.R22X and c.403 + 10G > T (Exon1 + 10), cDNA was
made by using High-Capacity cDNA Reverse Transcrip-
tion Kit (ABI) and sequencing was performed. Primers for
cDNA sequencing for the border between COQ2 exon 1
and 2 are 5'-CACGGTGGTGACTTGCAG-3' (Forward
primer sequence) and 5'-TGCTCCACGCATCAGAAT
AG-3' (Reverse primer sequence).
Table 4 The demographic, pathologic and clinical details
of the MSA patients






Total number 97 58 155









59.1 ± 8.7 (39–78) 64.7 ± 8.8 (48–83) 61.6 ± 9.1 (39–83)
Mean age at
death, SD






White (Caucasian) 93 47 140
African-American 1 4 5
Asian 2 0 2




Abbreviation: MSA-P parkinsonian variant of multiple system atrophy, MSA-C
cerebellar variant of multiple system atrophy, MSA-PC mixed type of multiple
system atrophy with parkinsonism and cerebellar ataxia, NA not available, PD
Parkinson’s disease, SD standard deviation. *One MSA patient was unclassified.
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For prediction of the functional consequences of variants
on COQ2 protein sequence, we used software programs
available on the internet, namely PolyPhen-2 (http://genet-
ics.bwh.harvard.edu/pph2/) [28] and SIFT (http://sift.jcvi.
org/) [29].
The results were shown in Table 1. Splice site predic-
tion of intronic variants identified in COQ2 were calcu-
lated by using the online bioinformatics tools, Human
Splicing Finder (version 2.4.1) [30]. See the URL. (http://
www.umd.be/HSF/HSF.html).
The protein domain search tools, TIGRFAMs database
(www.tigr.org/TIGRFAMs) [15] and Pfam database (http://
pfam.xfam.org/) [16] were used to elucidate the association
between variants and protein domains (Figure 1). We used
an online software of DOG (Domain Graph, version 2.0.1;
http://dog.biocuckoo.org/) to prepare publication-quality
figures of protein domain structures [31].
Statistical analysis
For each COQ2 mutation, comparisons of the frequency
of carriers of the minor allele between MSA patients and
(1) controls from our study, (2) EVS data, and (3) 1000
Genomes data were made using Fisher’s exact test. We
utilized a Bonferroni correction to adjust for multipletesting separately for these three sets of comparisons, after
which p-values ≤0.01 (MSA patients vs. controls, 5 tests),
≤0.0071 (MSA patients vs. EVS data, 7 tests), and ≤0.0071
(MSA patients vs. 1000 Genomes data, 7 tests) were con-
sidered as statistically significant. Note that only COQ2
variants for which information was obtained for both
MSA patients and the given comparison group of interest
were utilized when making comparisons. Additionally,
when combining data from our study and previously
published or publicly available data, we compared the
frequency of carriers of any COQ2 mutation found in
primary CoQ10 deficiency-1 (p.S109N, p.S146N, p.R197H,
p.N228S, p.L234fsX247, p.T297C, p.A302V p.R387X, and
p.N401fsX15; Table 2) [5-12] between MSA patient and
control groups using Fisher’s exact test (Table 3). All stat-
istical analysis was performed using R Statistical Software
(version 2.14.0; R Foundation for Statistical Computing,
Vienna, Austria).
Additional file
Additional file 1: For variants of COQ2 observed in this study,
comparisons of MSA patients with controls, with EVS data, and with
1000 Genomes data.
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